Asthma presents in various clinical forms and levels of severity and has a complex pathophysiology. Unbiased clustering was initially performed on clinical features, but the addition of biomarkers such as sputum and blood cellular profiles has led to the description of several phenotypes and enabled the prediction of responses to targeted therapies. Clusters of severe asthma include those on high-dose corticosteroid treatment, often with both inhaled and oral treatment, associated with severe airflow obstruction. Concordance between symptoms and sputum eosinophilia is observed in an eosinophilic inflammation-predominant group with few symptoms and late-onset disease who have a high prevalence of rhinosinusitis, aspirin sensitivity, and exacerbations. Sputum or blood eosinophilia is also a biomarker that can predict therapeutic responses to antibody-based treatments to block the effects of the T-helper-2 cytokine, interleukin-5. Low T-helper-2 expression predicts poor therapeutic response to inhaled corticosteroid therapy. Much less is known about 'non-eosinophilic' or non-T-helper-2 asthma. Clustering on transcriptomic and/or proteomic data is leading to definition of molecular phenotypes and potential mechanisms. The definition of endotypes and biomarkers of disease and therapeutic responses will pave the way towards personalized medicine and healthcare for asthma. For the clinician, these will translate into useful tools and means for managing patients with asthma, particularly severe asthma. Corresponding author : Kian Fan Chung, f.chung@imperial.ac.uk 
THE COMPLEXITY OF ASTHMA AND PHENOTYPING APPROACHES
Asthma is a disease with complex aetiologies and presentations with different natural histories and outcomes. Initially defined simply as a condition that causes symptoms such as wheezing, shortness of breath, chest tightness, and cough that vary over time in their occurrence, frequency, and intensity and associated with variable expiratory airflow, there has been the later recognition that there is an important inflammatory process occurring in the airways that underlies the pathophysiology. Treatment approaches for asthma have been based on this notion, such that anti-inflammatory treatments based mainly on inhaled corticosteroid therapies with supportive bronchodilator therapies using β-adrenergic agonists have become the uniformly applied treatments 1 . Guidelines for asthma management, first widely disseminated in the 1990s, have focused on a uniform stepwise escalation of treatments (inhaled corticosteroids and β-adrenergic bronchodilators) irrespective of the phenotype or aetiology, with the level of treatment given commensurate with the severity of asthma in a particular patient (Global Initiative for Asthma, GINA). However, this approach to asthma management, while successful in a large proportion of patients with asthma, was not effective in controlling asthma in a significant proportion of asthma patients. This group encompassed patients labelled as "difficult-to-treat asthma", with a large proportion being truly refractory or insensitive to the effects of asthma therapies, including corticosteroids and β-adrenergic agonists, patients that are now grouped under the umbrella term of "severe asthma" 2 .
In trying to understand the pathophysiology of severe asthma, it was quite clear that this group of patients was heterogeneous in terms of their presentation, comorbid factors, type of underlying inflammation, and degrees of response to asthma treatments. This heterogeneity of asthma is now recognised within the definition of asthma of the recent GINA guidelines (http://www.ginasthma.org/documents/4). Indeed, in severe asthma, phenotype-guided treatment has been recognised with recommendation for the use of sputum-guided treatment to reduce exacerbations and/or steroid dose, and with the recent use of targeted add-on anti-immunoglobulin E (IgE) treatment for severe allergic asthma and consideration of addition of leukotriene receptor antagonists for treating aspirin-exacerbated asthma. Despite these advances in the management of asthma, the science of phenotyping asthma itself has remained fairly rudimentary until recently. Clinicians and epidemiologists have been aware of the varied presentation of asthma, and epidemiologists of the different outcomes of asthma, particularly in childhood, and of the differences in responsiveness to currently available treatments.
With the application of cluster analysis, an unbiased statistical technique for grouping sets of data that have a degree of closeness, there has been real progress made in defining clinical phenotypes based on clinical-physiological characteristics. Clustering requires approaches that will group a set of objects depending on the degree of closeness to each other so that objects in the same group are more similar to each other than those in other groups (or clusters). It is used in exploratory data mining, and is a widely used technique for statistical data analysis used in many fields including the determination of phenotypes of asthma dependent on disease characteristics. Of the many clustering algorithms in use, one commonly applied to asthma phenotyping has been connectivity models such as hierarchical clustering based on distance connectivity or κ-means algorithm base by single mean cluster.
While the definition of phenotypes on the basis of clinical parameters is useful to the clinician, it does not allow for an understanding of the mechanism underlying the phenotypic class, which is necessary for providing a more rational approach to management. Inclusion of risk factors, triggers, and biomarkers of inflammation in the clustering has led to an improvement in understanding of the complex interactions of many risk factors and underlying inflammatory pathways involved in asthma. The availability of -omics data has opened up another dimension to asthma phenotyping as inclusion of such data in the analysis opens up the possibility of defining groups of asthma depending on the pathophysiological/molecular mechanisms leading to the definition of molecular phenotypes of asthma. Finally, when these mechanisms have been shown to be underlying the clinical-physiological inflammatory processes of that phenotype, we can then define endotypes of asthma 3 . Endotypes will be most useful in defining targets for the development of new therapies and treatments for different endotypes of asthma, an important path towards the personalisation of treatment approaches 4 . Integration of biological and -omics data with clinical-physiological inflammatory parameters is challenging and will require mathematical modelling such as machine learning approaches or network models; in fact, new methods for integrative data analyses are required to overcome the computational challenges of these methods 5 (Fig. 1) . This review will focus on the approaches to phenotyping asthma over the last 90 years, summarise the phenotypes of asthma that have been described so far, and point to the future directions of asthma phenotyping.
PHENOTYPES BASED ON CLINICAL-PHYSIOLOGICAL PARAMETERS
Clinicians have long recognised that asthma is a syndrome consisting of different phenotypes. Therefore, there have been clinical descriptors of asthma that can be loosely termed as "phenotype" based on essentially clinical-physiological parameters and biomarkers, a list of which is provided in table 1. One of the first clinical subgroups of asthma proposed has been based on the presence of allergic sensitisation with asthma, termed extrinsic asthma, as opposed to intrinsic asthma which is not associated with atopic disease, a division based on the notion that extrinsic asthma results from the exposure to common aeroallergens 6 . Extrinsic asthma was usually associated with a younger age of onset, while intrinsic asthma was usually associated with a later onset of asthma and a generally worse prognosis. Amongst the intrinsic group, late-onset asthma was a group of asthma with aspirin sensitivity and nasal polyposis that was usually associated with eosinophilia 7 . A recent systematic review of the literature regarding age of onset found that adults with early onset current asthma were more likely to be atopic and have more frequent symptoms compared with those with late-onset disease, who were more likely to be female, smokers, and with a greater level of fixed airflow obstruction. However, in both groups the prevalence of severe asthma was similar with few phenotypic differences between severe asthmatics regardless of age of onset 8 . Whether the entity of intrinsic asthma versus extrinsic asthma is valid anymore continues to be debated as the clinical and immunopathological features of these two conditions appear to be similar 9 . Another category of patients recognised in the late 1950s was that of therapeutic responders to oral corticosteroid therapies versus those who were non-responders (corticosteroid-insensitive) and with the observation that blood or sputum eosinophilia was a marker of responsiveness to oral corticosteroid treatment, one of the first biomarkers of therapeutic response to be described for asthma 10, 11 .
Other phenotypes have been recognised, which can be classified on the broad category according to causation, patterns of airflow obstruction, disease severity, and type of airway inflammation 12 (Table 1) . Asthma phenotypes according to patterns of airflow obstruction measured by peak expiratory flow rates or forced expiratory volume in one second (FEV 1 ) have been most studied. Fixed airflow limitation is recognised as a distinct phenotype of severe asthma found in up to 50% of patients who have a longer duration of disease, greater eosinophilic inflammation in sputum or blood, with thickening of the airways as seen on high resolution computed tomographic scans 13, 14 . A greater morbidity and mortality, particularly in severe asthma. The risk factors associated with frequent exacerbators include severe sinus disease, gastro-oesophageal reflux disease, recurrent chest infections, psychological factors, and obstructive sleep apnoea 16 . These patients are characterised by lower quality of life scores, higher sputum eosinophilia, and a more rapid decline in FEV 1 17 , and controlling the level of sputum eosinophilia with corticosteroid treatment led to a reduction in exacerbations in this phenotype, indicating the link between eosinophilia and exacerbations 18 . The role of triggers and precipitating factors in causing uncontrolled asthma and exacerbations may also be important in defining clinical clusters, but their direct effect remains unclear 19, 20 .
PHENOTYPING BASED ON CLUSTERING OF CLINICAL-PHYSIOLOGICAL DATA
An unbiased approach to defining phenotypes using clustering techniques has been started by using cohorts of asthma with a range of clinical severities, initially using clinical-physiological correlates only, with the Severe Asthma Research Program (SARP) adult and paediatric cohorts 21, 22 and the United Kingdom (UK) Leicester adult cohorts 23 being the pioneers in this rapidly expanding field. These studies reported phenotypes that have common, although not entirely similar, features that have already been recognized (Table 2) , such as patients with little airflow obstruction and activity of disease, patients with early age of onset of disease with an atopic background, and a more severe group of asthma patients associated with adult-onset disease and active airway smooth muscle area associated with an increased expression of T-helper type 1 (Th1) and Th2 cytokines measured in sputum supernatants was seen in these patients 15 . Frequent exacerbators are also a well-defined phenotype because of its major source of disease. Such clusters have been replicated in adult and paediatric cohorts in the Western world [24] [25] [26] [27] as well as in Korean and Japanese cohorts 28, 29 , with greater concordance in clusters related to severe asthma. Patients on high-dose inhaled corticosteroid therapy made up of clusters 4 and 5 of the adult SARP cohort, often taken together with oral corticosteroid treatment, are usually associated with severe airflow obstruction (Fig. 2) . In Korean patients with refractory asthma 30 , three of the four clusters described closely resembled clusters 4 and 5 of SARP, with the Korean cluster 4 consisting predominantly of male cigarette smokers. In The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study, the fifth cluster, described in adolescents and adults, was associated with aspirin sensitivity, in primarily white, female, and atopic patients with late-onset asthma, and with increased exacerbation rates 26 . In the Childhood Asthma Management Program Research Group, spectral clustering applied to clinical data from 1,041 children with asthma led to the description of five reproducible clusters differentiated on the basis of atopic burden, degree of airway obstruction, and history of exacerbations. Cluster grouping predicted long-term asthma control assessed by need for controller medication including oral prednisolone, and by longitudinal differences in lung function 27 .
The EU-funded Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) project has just published details of their paediatric and adult severe asthma cohorts 31, 32 . This cross-sectional assessment of adults with severe asthma, mild/ moderate asthma, and healthy controls from 11 European countries showed that patients with severe asthma had more symptoms and exacerbations (2.5 exacerbations versus 0.4 in the preceding 12 months) compared to patients with mild/moderate disease, with worse quality of life and higher levels of anxiety and depression. They also had a higher incidence of nasal polyps and gastro-oesophageal reflux with lower lung function. A preliminary report has shown four stable clusters derived from an analysis of eight clinical-physiological features, with one cluster consisting of well-controlled moderate-to-severe asthmatics, while the three other clusters of predominantly severe asthma consisted of (i) a group of late-onset severe asthmatics with history of smoking and chronic airflow obstruction, (ii) a group of chronic airflow obstruction but were non-smokers, and (iii) a group of obese female uncontrolled severe asthmatics with increased exacerbations, but with normal lung function 33 . The sputum eosinophil counts were highest in the two obstructed clusters. These clusters exhibited similarities with the clusters reported in the SARP and the Leicester cohorts.
New clinical groups, such as those associated with obesity, have also been defined in both the SARP and Leicester cohorts. This has now been confirmed in other analyses that have specifically examined the contribution of obesity 34, 35 . Two clusters of obese individuals were described: obese uncontrolled and obese well-controlled, and these asthma clusters differed from one another with regard to age of asthma onset, measures of asthma symptoms and control, exhaled nitric oxide (FeNO) concentration, and airway hyper-responsiveness, but were similar with regard to measures of lung function, airway eosinophilia, and serum IgE 34 . A group of obese women with late-onset asthma and frequent symptoms with high healthcare use, but with low sputum eosinophil counts, has also been reported 36 .
The finding of obesity associated clusters does not provide causation, but there is growing evidence that obesity itself may contribute to the inflammatory mechanisms of asthma 37 .
PHENOTYPING BASED ON SELECTED INFLAMMATORY BIOMARKERS
The addition of inflammatory markers such as blood eosinophil counts or sputum eosinophils or levels of FeNO added a new dimension to the phenotyping. There has been confirmation that sputum eosinophils can be used as biomarkers of corticosteroid-sensitive asthma 38, 39 , while non-eosinophilic asthma, defined by low sputum eosinophilia, is generally insensitive to the effects of corticosteroids. In fact, using sputum eosinophil counts to determine the amount of corticosteroid therapy needed to control asthma was superior to using symptoms in improving asthma control 18 . Anti-inflammatory therapy with corticosteroids caused significant improvements in airflow obstruction in eosinophilic asthma, but not in persistently non-eosinophilic asthma. Non-eosinophilic asthma was more predominant in mild-to-moderate asthma, just as neutrophilic asthma is also predominant in severe refractory asthma 40, 41 .
Blood eosinophil counts
Blood eosinophilia has now become an area of interest as a biomarker for elevated T2 cytokines. Interest has turned towards the use of blood eosinophilia as a biomarker of Th2 high and as a biomarker for responsiveness to anti-Th2 cytokines such as anti-interleukin 5 (anti-IL-5) or anti-IgE therapies for severe asthma. Blood eosinophilia is linked to elevated Th2 cytokines, but this relationship is not as strong as sputum eosinophilia 42 . On the other hand, in a group of uncontrolled treated asthmatic patients, blood eosinophil counts could accurately predict eosinophilic asthma 43 . Blood eosinophilia has also been linked to worse outcome measures in asthma 44, 45 , to more severe disease 46 , as a predictor of response to anti-IL-5 therapies [47] [48] [49] [50] , and to anti-IgE therapy 51, 52 and to responsiveness to corticosteroid therapies 53, 54 . Because it is easier to obtain blood eosinophil counts from patients than sputum eosinophil counts, blood eosinophil counts are now being used more widely in the clinic.
Exhaled nitric oxide
Similar to blood eosinophil counts, FeNO has been associated with worse asthma outcomes, the need for corticosteroid therapy, and responsiveness to corticosteroid therapy 55 . FeNO was predictive of response to anti IgE 51 . However, levels of FeNO have not been predictive of response to anti-IL-5 therapy 56 . On the other hand, therapies with anti-IL-4Rα (interleukin-4 receptor a) or anti-IL-13 antibodies caused a reduction in FeNO, but had no effect on blood eosinophil counts [57] [58] [59] .
Serum periostin
Periostin is a member of the Th2 genes induced by IL-13. Serum periostin has been shown to correlate with airway and sputum eosinophilia 60 and is associated with Th2 inflammation 42 . Serum periostin has also been shown in a Japanese asthma cohort on inhaled corticosteroid treatment to denote those with chronic airflow obstruction 61 . Serum periostin level was a predictor of response of FEV 1 to anti-IL-13 therapy in patients with moderate-to-severe asthma 57 .
PHENOTYPING BASED ON CLUSTERING OF CLINICAL-PHYSIOLOGICAL INFLAMMATORY BIOMARKERS
In the Leicester cohorts where the sputum eosinophil count was a central parameter used, two clusters (the early onset atopic and the non-eosinophilic obese) were common to the milder-moderate and the moderate-severe cohorts 23 . However, in the more severe cohort with refractory asthma, there was a marked discordance in two clusters between symptom expression and eosinophilic airway inflammation (early onset symptom predominant and late-onset inflammation predominant). However, in both discordant subgroups, an inflammation-guided management was superior in leading to a reduction in exacerbation frequency in the inflammation-predominant cluster and a dose reduction of inhaled corticosteroid in the symptom-predominant cluster. Thus, documentation of the sputum eosinophil level was useful in the therapeutic sense.
In the SARP cohort, use of the inflammatory phenotypes assessed by sputum cell counts led to the identification of four phenotypic clusters with two clusters of mild-to-moderate early onset allergic asthma with paucigranulocytic or eosinophilic sputum inflammatory cell patterns, and two other clusters with either neutrophilic or mixed inflammatory patterns with moderate-to-severe asthma with frequent healthcare use despite treatment with high doses of inhaled or oral corticosteroids and also reduced lung function 62 . A similar report from the cohort in Newcastle, Australia, described that patients with neutrophilic inflammation had a greater frequency of primary care doctor visits for asthma exacerbations and a high prevalence of chest infections in the previous 12 months, of rhinosinusitis and of gastro-oesophageal reflux symptoms when compared to eosinophilic asthma 62 .
Addition of other inflammatory biomarkers including FeNO, bronchoalveolar lavage (BAL) cell counts and levels of serum IgE was also examined in the SARP cohort, leading to the definition of six clusters that included one healthy control cluster and five other asthma clusters. In these five clusters that were similar to the previously reported five clusters of SARP obtained from clustering on only clinical-physiological parameters 63 , there was a late-onset eosinophilic asthma cluster associated with nasal polyposis and sinusitis 64 , a cluster also described in the Leicester cohort 23 .
CLINICAL VALUE AND STABILITY OF PHENOTYPES
Having defined clusters, is there any value of applying cluster analysis into the clinic? First, the stability of clusters need to be determined, an important issue given that asthma is a variable condition punctuated by exacerbation of the disease process. Adult asthma phenotypes identified by a clustering approach on two occasions, 10 years apart, in three separate cohorts of mild-moderate asthma were reported to be highly consistent, with the phenotypes mainly characterised by the level of asthma symptoms, allergic state, and pulmonary function 65 . This may not be surprising considering that these were mild-moderate asthmatics. In the BIOAIR (the study of longitudinal assessment of clinical course and BIOmarkers in Severe Chronic AIRway disease) cohort of more severe asthma, phenotypes determined by biomarkers such as blood eosinophil or neutrophil counts and FeNO were less stable than those defined by physiological variables such as FEV 1 66 . The definition of asthma phenotypes may be improved by repeated measurements to account for the fluctuations in lung function in asthma, particularly severe asthma.
Can application of cluster analysis predict outcomes in individual patients? In a recent analysis where clusters were identified according to the SARP definition of five clusters in a cohort of severe asthma that has been followed-up for at least one year, none of the clusters predicted significant outcomes 67 . It has been suggested that the inclusion and integration of prospective data such as the effect of therapeutic interventions, environmental data regarding pollution for example, and triggers for clustering could enhance their value in the clinic.
MOLECULAR PHENOTYPING USING MICROARRAY APPROACHES
The Th2-high molecular phenotype was the first to be defined by Woodruff et al. 68 who examined the gene signature of airway epithelial brushings from mild-moderate asthmatics according to the degree of expression of IL-13-inducible genes, periostin, chloride channel regulator 1, and serpin peptidase inhibitor (Fig 3) . The Th2-high asthmatic patients, constituting about 50% of the cohort, had a greater degree of bronchial hyper-responsiveness, higher serum IgE levels, greater blood and airway eosinophilia, sub-epithelial fibrosis, and airway mucin gene expression, and responded well to inhaled corticosteroid therapy 69 . Those with a low Th2 signature showed little or no response to inhaled corticosteroid therapy. The frequency of the Th2-high molecular phenotype has been analysed by direct measurement of sputum cell gene expression of IL-4, IL-5, and IL-13, with 70% of mild-to-moderate asthmatics defined as Th2-high, characterised by more severe measures of asthma and increased blood and sputum eosinophilia 42 .
Using whole genome gene expression microarrays, Baines et al. 70 found that out of 277 differentially expressed genes between asthma inflammatory phenotypes, a sixgene signature that included Charcot Leyden crystal protein, carboxypeptidase A3, deoxyribonuclease 1-like 3, IL-1β and CXCR2 chemokine receptor could discriminate eosinophilic asthma from the other inflammatory types including neutrophilic asthma. Using gene expression profiling of induced sputum and unsupervised hierarchical clustering of these expression profiles led to the description of three phenotypes: (i) chronic airflow obstruction and less well-controlled asthma, increased FeNO, and sputum eosinophils; (ii) airflow obstruction and higher sputum neutrophils; and (iii) higher sputum macrophages and lower eosinophils and neutrophils, and lung function in normal range. Genes in the IL-1 and tumour necrosis factor (TNF)-a/nuclear factor-κB pathways were also overexpressed and correlated with clinical parameters and neutrophilic airway inflammation.
Using a microarray platform to analyse bronchial airway epithelial cell gene expression in relation to the asthma biomarker fractional FeNO in SARP, five asthma clusters/phenotypes with distinct clinical, physiological, cellular, and gene transcription characteristics were described 71 . Genes related to type 2 inflammation were present, but other novel pathways, including those related to neuronal function, Wnt pathways, and actin cytoskeleton, were defined.
In UBIOPRED, using a semi-supervised machine-learning approach, a high mucosal eosinophils, high biopsy CD3 + , CD4 + , and CD8 + T-cells, high FeNO and oral corticosteroid-dependent phenotype was derived from eight gene-signature sets applied to airway biopsy and brushings 72 . Another phenotype was characterized by high sputum eosinophilia, high biopsy CD8 + T-cells, and obesity. These phenotypes were not only dictated by a Th2-high gene signature, but also by a Th1 signature, in addition to corticosteroid and oxidative response gene-sets.
Thus, these above approaches have led to the definition of novel non-Th2 pathways or genes in addition to the Th2 pathways/genes that may contribute to the molecular phenotyping of asthma. This is particularly true of pathways that are related to neutrophilic-type inflammation as defined in some studies. Bacterial colonization in the airways of patients with severe asthma could contribute to neutrophilic asthma 73, 74 . Defective phagocytosis of bacteria or of apoptotic cells by macrophages has also been reported in severe asthma 75, 76 . More recent evidence, employing analysis of the microbiome using 16s, has shown differences in the bacterial organisation in the lower airways of patients with severe asthma by the presence of Streptococcus spp and Haemophilus influenzae associated with eosinophilia. Goleva et al. 77 further showed that Haemophilus parainfluenzae overexpressed in severe asthma can directly induce corticosteroid resistance. Corticosteroids themselves can contribute to the neutrophilia to some extent, and even Th1 factors could play a role 78, 79 .
Th17 cells have also been implicated as a cause of neutrophilia in severe asthma, perhaps even contributing to corticosteroid insensitivity 80 . In fact, there is evidence for an upregulation of the Th17 pathway in poorly controlled non-Th2 molecular phenotype 80, 81 . Brodalumab, a human anti-IL-17Rα monoclonal antibody, had no effect on asthma control scores, symptom-free days, and FEV 1 in patients with inadequately controlled moderate-to-severe asthma on inhaled corticosteroid therapy. A high-reversibility subgroup with a post-bronchodilator FEV 1 improvement of 20% or more showed a significant improvement in ACQ score 82 . The inflammasome could underlie neutrophilic asthma and has been shown to be activated in sputum cells from patients with severe neutrophilic asthma 83, 84 .
PHENOTYPE-DRIVEN THERAPIES
With the recognition that the cytokines that were first identified to be produced from Th2 cells, such as IL-4, IL-5, and IL-13, can also be produced from other non-Th2 cell types, such as eosinophils, mast cells, and ILC-2, this inflammatory molecular phenotype has been labelled as Type-2 (T2) inflammation. Members of the Th2 pathway, such as IL-5, IL-4, and IL-13, have been targeted using humanised monoclonal antibodies directed towards these cytokines or their receptors and used as treatments for severe asthma 85 . Demonstration of efficacy of new therapies will depend in part on the precision by which patients can be endotyped for specific therapies 4, 86 . Initially, the anti-IL-5 antibody mepolizumab was shown to have no beneficial effects on symptom control or exacerbations in a cohort of moderately severe asthmatics, despite reducing the levels of blood eosinophilia 87 . However, when the patients were recruited with having more severe asthma associated with a history of exacerbations and with persistent sputum or blood eosinophilia, mepolizumab decreased exacerbations, led to a reduction in the use of oral corticosteroids, and improved symptoms and lung function compared with placebo 56, 88 .
A blood eosinophil count of 150 cells/μl or more was associated with a reduction in exacerbation rate of 72% compared with a reduction of 30% in those with a blood eosinophil count of less than 150 cells/μl. Similar effects have also been demonstrated with another anti-IL-5 antibody, reslizumab, or an anti-IL-5 receptor antibody, benralizumab, in patients with blood eosinophilia 50, 89 . However, we should still strive to find even better predictor biomarkers.
In patients with uncontrolled asthma despite use of inhaled corticosteroids and long-acting β2 agonists, treatment with lebrikizumab, an anti-IL-13 antibody, improved FEV 1 by 8.2% above the baseline value in patients with a high concentration of serum periostin, whereas patients with a low concentration of serum periostin showed no FEV 1 response 57 .
These studies emphasise the importance of developing biomarkers for pinpointing those responders so that the right patient will get the right treatment, the real objective of personalised medicine 90 . What is currently missing is treatments focused on the non-Th2 pathways, although treatments based on targeting IL-17, CXC chemokines, and TNF-α have so far failed to show any benefits in severe asthma 85 .
CONCLUDING REMARKS
There have been important advances in the last 15 years in the definition of phenotypes, initially using clinical-physiological parameters and later with the inclusion of omics data, that has led to some definition of Th2 and non-Th2 pathways (Table 3) . Much needs to be done to identify the non-Th2 pathways and their interactions with the Th2 pathway. At the time of writing, the data from UBIO-PRED cohort have not been published yet, although there have been preliminary presentations at international meetings of some of the clustering findings based on an omics approach 72, 84, 91 . What will emerge from these analyses is that there will likely be well-defined molecular phenotypes or endotypes underlined by multiple pathways that will include components of both the Th2 and nonTh2 pathways. The challenge will come in dissecting out the important pathway or gene components that are most important in a particular patient using the tools available for progressing systems medicine. The introduction of targeted therapies, particularly against Th2-associated cytokines such as IL-4, IL-5, and IL-13, has contributed to the validation of certain phenotypes such as the IL-5-dependent eosinophilic frequent exacerbator phenotype.
Other non-Th2 components may be involved such as the inflammasome activation pathways, as has been reported recently 92 . It is important that any phenotype be validated in other independent cohorts, and therefore this area needs to represent a collaborative effort across major centres and also across national and continental boundaries to take into account the influence of local environmental and genetic factors.
Finally, it is important that the clinician is helped by knowledge of the phenotype of the asthma patient. This could be to provide longterm prediction of outcomes and to find out which specific treatments may benefit selected phenotypes. In effect, many would argue that phenotypes should confer predictive value and should relate to clinically meaningful outcomes. These aspects need to be addressed. Predictive value may be obtained if indicators of the day-to-day variability of the condition are included in the analysis. The -omics approach should contribute towards the availability of new, specific treatments while defining the appropriate patient groups for these specific treatments 90 . Biomarkers that are easily measurable and accessible in the clinic to help the clinician in classifying patients would represent an advance. Blood eosinophil counts are now useful in the clinic in defining the T2-phenotype, but other more precise biomarkers are needed for the definition of other phenotypes. Application of phenotyping to the clinic is the cornerstone of the progress towards personalised medicine 4 .
